GBT - Global Blood Therapeutics, Inc.
| Previous Close | 48.02 |
| Open | 48.92 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1800 |
| Day's Range | 47.43 - 48.92 |
| 52 Week Range | 30.15 - 64.94 |
| Volume | 529,913 |
| Avg. Volume | 922,706 |
| Market Cap | 2.885B |
| Beta (3Y Monthly) | 0.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.64 |
| Earnings Date | Nov 4, 2019 - Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 91.85 |
- GlobeNewswire
GBT Reports Recent Business Progress and Second Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the second.
- GlobeNewswire
GBT Announces Participation at the 2019 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2019 Wedbush PacGrow Healthcare.
- GlobeNewswire
GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on August 1, 2019, the compensation committee of GBT’s.
- Kiplinger
5 Biotech Stocks to Buy for Blockbuster Potential
Biotechnology has boomed over the past few decades as our understanding of living organisms and the human machine has swelled. As a result, biotech stocks have become some of the most exciting growth plays on Wall Street.And their potential to deliver sky-high returns is especially explosive when they're developing a drug with blockbuster potential.Blockbuster drugs are those popular treatments that generate annual sales of at least $1 billion. They're uncommon: A drug must have the right combination of price and number of potential patients, so only a handful of treatments at any given time even have the potential to become billion-dollar products. And not all of them live up to their potential.So how can you pinpoint biotech stocks with these kind of superstar drugs in the pipeline? We suggest turning to Wall Street's pros.Here are five promising biotech stocks to buy for their blockbuster-drug potential. TipRanks data shows that all five stocks boast a "Strong Buy" consensus among the Wall Street analysts covering them, based on ratings given during the past three months. SEE ALSO: The 20 Best Small-Cap Dividend Stocks to Buy
- Zacks
Should You Pick Up Novartis (NVS) Before Q2 Earnings?
Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should expect heading into its Q2 2019 earnings release on Thursday.
- Zacks
Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA
The FDA accepts Novartis' (NVS) BLA for crizanlizumab and grants Priority Review to the same to prevent pain crises in patients with sickle cell disease.
- GlobeNewswire
GBT and Advocates Launch Disease Awareness Campaign Focused on Breaking Down Stigmas Associated with Sickle Cell Disease
Global Blood Therapeutics, Inc. (GBT) (GBT), in partnership with sickle cell community-based organizations (CBOs), today announced the launch of Sickle Cell Speaks, a national campaign focused on breaking down stigmas associated with sickle cell disease (SCD). Sickle Cell Speaks is designed to bring together a community of people, from patients to caregivers to friends and relatives, whose lives are affected by SCD. Sickle Cell Speaks aims to inspire hope by showcasing stories of strength and to dispel the misconceptions about SCD.
- American City Business Journals
Local researcher part of 'exciting' sickle cell drug trial
Currently, there are only two Food & Drug Administration treatments that are approved for sale and use in the U.S.
- Motley Fool
Why BlackBerry, AeroVironment, and Global Blood Therapeutics Slumped on Wednesday
Find out how earnings hurt some of these stocks.
- GlobeNewswire
Global Blood Therapeutics Prices a $200.0 Million Common Stock Public Offering
Global Blood Therapeutics, Inc. (GBT) (GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced the pricing of its underwritten public offering of 3,375,527 shares of its common stock for gross proceeds of approximately $200.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by GBT. In addition, GBT has granted the underwriter a 30-day option to purchase up to an additional $30.0 million of additional shares of common stock. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.
- Benzinga
The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ...
- GlobeNewswire
Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
Global Blood Therapeutics, Inc. (GBT) (GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced an agreement to sell approximately $200.0 million in shares of its common stock in a registered underwritten public offering. In addition, GBT has granted the underwriter a 30-day option to purchase up to approximately $30.0 million in shares of its common stock. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. GBT intends to use the net proceeds from the offering and its existing capital resources to fund its clinical development of voxelotor for the treatment of sickle cell disease, including its ongoing clinical studies, its activities in preparation for the potential commercial launch of voxelotor, if approved by the U.S. Food and Drug Administration, and future clinical trials of voxelotor and other product candidates that GBT may elect to pursue, including inclacumab, and to fund its other research and development activities and for working capital and general corporate purposes. GBT may also use a portion of the net proceeds to in-license, acquire or invest in new business, technology or assets, although it has no material agreements, commitments or understandings in place.
- Simply Wall St.
Should You Be Concerned About Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) Historical Volatility?
If you're interested in Global Blood Therapeutics, Inc. (NASDAQ:GBT), then you might want to consider its beta (a...
- Insider Monkey
Is Global Blood Therapeutics Inc (GBT) A Good Stock To Buy?
Before we spend countless hours researching a company, we'd like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- Schaeffer's Investment Research
Global Blood Therapeutics Stock Options Hot During Sell-Off
Guggenheim says to buy the stock's dip
- GlobeNewswire
GBT Announces Updated 24-Week Efficacy Data from All Patients Enrolled in Phase 3 HOPE Study Showing Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor
Global Blood Therapeutics, Inc. (GBT) (GBT) today announced new results from its Phase 3 HOPE Study of voxelotor in patients ages 12 and older with sickle cell disease (SCD). The findings from 274 adolescents and adults treated with voxelotor showed the HOPE Study met its primary endpoint of an improvement in hemoglobin greater than 1 g/dL at 24 weeks with voxelotor 1500 mg compared with placebo, with a favorable safety and tolerability profile.
- Zacks
Options Traders Expect Huge Moves in Global Blood Therapeutics (GBT) Stock
Investors need to pay close attention to Global Blood Therapeutics (GBT) stock based on the movements in the options market lately.
- Motley Fool
A Biotech Stock to Watch Now
Investors will get additional insight into a potential new treatment for sickle cell disease on Friday.
- GlobeNewswire
GBT Awards More than $200,000 in Grants to Five Nonprofit Organizations through New ACCEL Program Aimed at Improving Access to Healthcare for People Living with Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., June 10, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that five nonprofit organizations have been awarded more than.
- Zacks
Why Is Global Blood (GBT) Up 2% Since Last Earnings Report?
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
GBT Announces Upcoming Data Presentations at 24th European Hematology Association (EHA) Congress Supporting Voxelotor Sickle Cell Disease Program
Phase 3 HOPE Study 24-Week Efficacy Results from Full Patient Cohort to be Presented During Presidential Symposium New Drug Application (NDA) Submission Planned for Voxelotor.
- Zacks
Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1
Global Blood (GBT) reports narrower-than-expected loss in the first quarter of 2019.
- Associated Press
Global Blood: 1Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of 87 cents per share. The results surpassed Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment ...
